ID   OCI-Ly18
AC   CVCL_1880
AS   CVCL_9551
SY   OCI-LY18; OCI-LY-18; OCILY18; OCI-Ly 18; Ly18; LY18
DR   BioSample; SAMN03473448
DR   Cosmic; 1295513
DR   Cosmic; 1517651
DR   Cosmic; 1541906
DR   Cosmic; 1636683
DR   Cosmic; 2276334
DR   DepMap; ACH-001616
DR   DSMZ; ACC-699
DR   GEO; GSM380131
DR   GEO; GSM552456
DR   GEO; GSM1374785
DR   Progenetix; CVCL_1880
DR   Wikidata; Q54931770
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   PubMed=1311715;
RX   PubMed=8574164;
RX   PubMed=11807979;
RX   PubMed=19278952;
RX   PubMed=26727417;
WW   http://www.innovationbridge.com/uhn/diffuse-large-b-cell-lymphoma-cell-lines?categories=32&communities=5&forums=&organizations=&tags=
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   From: Ontario Cancer Institute (OCI); Toronto; Canada.
CC   Doubling time: ~30-40 hours (DSMZ).
CC   Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg80Ter (c.237_238CC>TT) (c.237_238delinsTT) (p.Pro94Leu, c.280_281CC>TT); Zygosity=Homozygous (DepMap).
CC   Omics: Array-based CGH.
CC   Omics: CNV analysis.
CC   Omics: miRNA expression profiling.
CC   Omics: Transcriptome analysis.
CC   Misspelling: OCI-LZ18; In BioSample SAMN03473448.
CC   Misspelling: SU-DHL-18; In Cosmic 1295513.
CC   Derived from sampling site: Pleural effusion.
ST   Source(s): DepMap; DSMZ
ST   Amelogenin: X
ST   CSF1PO: 10,12
ST   D13S317: 10,12
ST   D16S539: 11,13
ST   D18S51: 15,19
ST   D21S11: 31
ST   D3S1358: 14,15
ST   D5S818: 11,12
ST   D7S820: 10,12
ST   D8S1179: 10,13
ST   FGA: 19,21
ST   Penta D: 10
ST   Penta E: 5,14
ST   TH01: 6,9
ST   TPOX: 8,11
ST   vWA: 15,19
DI   NCIt; C8851; Diffuse large B-cell lymphoma
DI   ORDO; Orphanet_544; Diffuse large B-cell lymphoma
OX   NCBI_TaxID=9606; ! Homo sapiens
SX   Male
AG   56Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 16-12-21; Version: 22
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001).
//
RX   PubMed=1311715; DOI=10.1172/JCI115642;
RA   Chang H., Messner H.A., Wang X.-H., Yee C., Addy L., Meharchand J.,
RA   Minden M.D.;
RT   "A human lymphoma cell line with multiple immunoglobulin
RT   rearrangements.";
RL   J. Clin. Invest. 89:1014-1020(1992).
//
RX   PubMed=8574164; DOI=10.3109/10428199509059672;
RA   Chang H., Blondal J.A., Benchimol S., Minden M.D., Messner H.A.;
RT   "p53 mutations, c-myc and bcl-2 rearrangements in human non-Hodgkin's
RT   lymphoma cell lines.";
RL   Leuk. Lymphoma 19:165-171(1995).
//
RX   PubMed=11807979; DOI=10.1002/gcc.10025;
RA   Mehra S., Messner H.A., Minden M.D., Chaganti R.S.K.;
RT   "Molecular cytogenetic characterization of non-Hodgkin lymphoma cell
RT   lines.";
RL   Genes Chromosomes Cancer 33:225-234(2002).
//
RX   PubMed=19278952; DOI=10.1182/blood-2009-01-202028;
RA   Li C., Kim S.-W., Rai D., Bolla A.R., Adhvaryu S., Kinney M.C.,
RA   Robetorye R.S., Aguiar R.C.T.;
RT   "Copy number abnormalities, MYC activity, and the genetic fingerprint
RT   of normal B cells mechanistically define the microRNA profile of
RT   diffuse large B-cell lymphoma.";
RL   Blood 113:6681-6690(2009).
//
RX   PubMed=26727417; DOI=10.3109/10428194.2015.1108414;
RA   Drexler H.G., Eberth S., Nagel S., MacLeod R.A.F.;
RT   "Malignant hematopoietic cell lines: in vitro models for double-hit
RT   B-cell lymphomas.";
RL   Leuk. Lymphoma 57:1015-1020(2016).
//